Skip to main content

Table 1 Characteristics of HIV-infected patients at initiation of antiretroviral therapy in ten African countries, 2010–2012 (N = 3579)

From: Trends in hepatitis B virus testing practices and management in HIV clinics across sub-Saharan Africa

 

Benin

Burkina Faso

Cameroon

Cote d’Ivoire

Kenya

Senegal

South Africa

Togo

Uganda

Zambia

Number of sites

1

1

1

3

1

1

1

1

1

1

Cities

Cotonou

Bobo Dioulasso

Limbé

Abidjan

Eldoret

Dakar

Stellenbosch

Lomé

Kampala

Lusaka

Type of care

Tertiary

Tertiary

Tertiary

Primary / Tertiary

Tertiary

Tertiary

Tertiary

Tertiary

Tertiary

Primary

Number of patients included (proportion of total population followed)

300

(30%)

300

(21%)

298

(~30%)

900

(20%)

299

(1%)

297

(91%)

300

(16%)

300

(13%)

285

(7%)

300 (~10%)

Median age in years (IQR)

35 (30–42)

35 (30–42)

38 (32–44)

38 (33–45)

37 (32–44)

41 (35–49)

38 (33–46)

35 (30–43)

35 (28–42)

37 (31–42)

Female sex (%)

198 (66.0)

216 (72.0)

196 (65.8)

581 (64.6)

190 (63.5)

179 (60.3)

193 (64.3)

197 (65.7)

191 67.0)

162 (54.0)

Type of ART (%)

 2 NRTI +1 NNRTI

298 (99.3)

269 (89.7)

298 (100)

786 (87.3)

291 (97.3)

286 (96.3)

298 (99.3)

287 (95.7)

253 (88.8)

295 (98.3)

 3 NRTI

0 (0.0)

0 (0.0)

0 (0.0)

22 (2.5)

0 (0.0)

2 (0.7)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

 2 NRTI +1 PI

2 (0.7)

31 (10.3)

0 (0.0)

92 (10.2)

8 (2.7)

9 (3.0)

2 (0.7)

13 (4.3)

32 (11.2)

5 (1.7)

TDF (%)

39 (13.0)

87 (29.0)

191 (64.1)

303 (33.7)

122 (40.8)

122 (41.1)

243 (81.0)

44 (14.7)

61 (21.4)

265 (88.3)

HBsAg-positivity (%)

5/35 (14.3)

16/76 (21.1)

2/12 (16.7)

10/37 (27.0)

0/2 (0.0)

25/135 (18.5)

13/279 (4.7)

6/30 (20.0)

4/94 (4.3)

7/59 (11.9)

  1. IQR: interquartile range, ART: antiretroviral therapy, NRTI: nucleoside reverse-transcriptase inhibitors, NNRTI: non-nucleoside reverse-transcriptase
  2. Inhibitors, PI: protease inhibitors, TDF: tenofovir; HBsAg: Hepatitis B surface antigen